CYRAMZA® Improves Overall Survival in Advanced Gastric Cancer

June 27th, 2014

In a multinational double-blind phase III trial, targeting VEGFR-2 signaling with CYRAMZA® , improved overall survival in patients with previously treated advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. CYRAMZA® is the first biological treatment that has demonstrated survival benefit when given as a single agent in this patient population. This study was published in the Lancet, 2014.